Safety and tolerance in the use of Shock Wave Therapy in people with upper limb lymphedema after breast cancer treatment

Phase 2

• Conditions: GATA2 Deficiency, Breast Cancer Lymphedema; C16.320.314; C15.604.496.160

• Registration Number: RBR-7xpmy5
• Lead Sponsor: Patricia Lima Ventura

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-07-27
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

Women over 18; Women with lymphedema secondary to unilateral breast cancer surgery with an axillary approach (considered lymphedema when there is a difference in perimetry bigger or equal 2.00 cm in at least one point on the affected upper limb in relation to the contralateral one);Those who have undergone complex physical therapy (CFT) in the last year and have controlled lymphedema (with no changes in the last 30 days);Those who agree to participate in the research and sign the Informed Consent Form.

Exclusion Criteria

Those with local or remote recurrence;Women with bilateral breast cancer;Those undergoing chemotherapy or radiation therapy;Women with a postoperative period less than six months after the axillary approach; Presence of dermal changes (local signs and symptoms such as hyperemia, hyperthermia, hyperpigmentation, pustules and other skin changes); Report of autoimmune diseases (dermatomyositis, nephropathy, lupus erythematosus, morphea, psoriasis, pemphigus vulgaris, scleroderma); Report of osteomioarticular disease in a member homolateral to the surgery; Women with amputation of a limb; Be illiterate or have difficulty reading and interpreting text;Cognitive and psychiatric disorders.

Study & Design

• Study Type: Intervention
• Study Design: Not specified